Skip to main
ACIU
ACIU logo

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA's pipeline showcases promising developments in neurodegenerative disease therapies, particularly the PD active immunotherapy ACI-7104.056, which has exhibited a significant 20-fold increase in antibodies against pathogenic aSyn variants, highlighting its potential efficacy. Additionally, the company’s NLRP3 program is poised for increased interest, especially with the forthcoming results from the EVOKE trial focusing on Alzheimer's Disease, which could further validate its therapeutic approach. These advancements, combined with a strategic emphasis on safe delivery methods for monoclonal antibodies, position AC Immune favorably within the evolving Alzheimer’s treatment landscape, enhancing its outlook for future growth and success.

Bears say

AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, highlighting ongoing financial challenges. The company is exposed to various risks typical of the biopharmaceutical sector, including potential unfavorable clinical outcomes, regulatory uncertainties, and the complexities of navigating a price-sensitive commercial landscape. These factors contribute to a negative outlook for the company's stock, as they could impact future revenue generation and profitability prospects.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Nov 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.